You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Acute Disseminated Encephalomyelitis (ADEM)

    SBC: TRIANGLE THERAPEUTICS INC.            Topic: NIAID

    PROJECT SUMMARY Acute disseminated encephalomyelitis (ADEM) is an acute autoimmune disease that can present with fever and ataxia as well as loss of consciousness and coma. ADEM largely affects children, is driven by T and B lymphocytes aberrantly activated against a myelin antigen, and is strongly associated with a prior infection or immunization. There is no FDA-approved therapy for the treatmen ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Combined Cardiomyopathy, e.g., of Cancer Chemotherapeutics, and Proarrhythmia for Cardiotoxicity Clinical Trials-in-a-Dish (CTiD) with iPSC-Derived Cardiomyocytes

    SBC: VALA SCIENCES, INC.            Topic: NHLBI

    Cardiotoxicity is a leading cause of drug discovery attrition across all of preclinical and clinical drug discovery. While the FDA and the Comprehensive in vitro Proarrhythmia Assay initiative (CiPA) are focused primarily on predicting proarrhythmic effects, drug attrition due to cardiomyopathy, or primary cardiac cytotoxicity, may be even more prevalent, is typically currently only carried out vi ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Light-directed therapy of squamous cell head and neck cancer with a novel dual-acting chemotherapeutic.

    SBC: LIGHT SWITCH BIO, LLC            Topic: 102

    PROJECT SUMMARY. In this Phase I STTR project, Light Switch Bio will collaborate with Virginia Commonwealth University and the University of Pennsylvania for the early-stage development of IR-Platin, a first-in-class photoactivated chemotherapy for treatment of head and neck squamous cell carcinoma (HNSCC), the sixth leading cancer worldwide. Most patients with HNSCC present with advanced disease ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Factor H Fc fusions as novel therapeutics for Burkholderia pseudomallei infections

    SBC: Planet Biotechnology Incorporated            Topic: NIAID

    Burkholderia pseudomallei (Bp) is the causative agent of melioidosis, a major cause of morbidity and septic death in tropical/subtropical regions worldwide. It is particularly virulent in diabetic patients and is also considered a Tier 1 select agent due to its potential use as a bioweapon. These bacteria are naturally resistant to many antibiotics and there are currently no vaccines available. Th ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. An immunotherapeutic IgY formulation against norovirus diarrhea

    SBC: SCALED MICROBIOMICS LLC            Topic: NIAID

    Project Summary/Abstract for STTR Phase I Application: An immunotherapeutic IgY formulation against norovirus diarrhea Human norovirus (HuNoV) infects millions of people globally each year, causing diarrheal illness resulting in more than 200,000 deaths annually, particularly in the very young, the very old, and the immunocompromised. There is currently neither an effective vaccine nor effective t ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Substance Use Disorder Artificially Intelligent chatbot for screening, assessment and referral: SUD Bot

    SBC: Clinic Chat LLC            Topic: NIDA

    ABSTRACT The opioid epidemic is considered one of the most severe public health crises we are facing in the U.S. and is worsened by use of stimulants such as methamphetamine. The US Preventive Services Task Force (USPSTF) recommends screening for unhealthy drug use accompanied by offers of and referrals to services that include accurate diagnosis, effective treatment and appropriate care of a subs ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Inducible HMGB1 antagonist for viral-induced acute lung injury.

    SBC: SIGMOVIR BIOSYSTEMS, INC.            Topic: NHLBI

    For more than a decade, our work has focused on development of therapeutic interventions for viral- and bacterial-induced acute lung injury (ALI) and the more severe acute respiratory distress syndrome (ARDS). Significantly, we identified the Toll-like receptor 4 (TLR4) signaling pathway as key to the host response to influenza and secondary bacterial infection following influenza. We also identif ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Prevention and mitigation of acute traumatic coagulopathy and bleeding

    SBC: HEMATHERIX LLC            Topic: NHLBI

    Project Summary/Abstract Hematherix is developing superFVa for the treatment of acute traumatic coagulopathy (ATC). Mortality rates with traumatic hemorrhage often exceed 40%, exposing an unmet clinical need for targeted drug development. ATC develops early on as the consequence of severe trauma and shock, prior to additional iatrogenic effects. ATC is distinct from other coagulopathies and is cha ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Testing the effects of a selective calpain-2 inhibitor on spontaneous recurrent seizures in mouse models of epilepsy

    SBC: NEURAEGIS INC            Topic: 103

    AbstractEpilepsy is the most prevalent neurological diseases after migraines. Current antiepileptic drug treatments mainly attempt to reduce excitation or enhance inhibition in order to control seizures. Unfortunately, such therapeutics result in a number of undesirable side-effects, and demonstrate limited efficacy against drug- resistant cases of epilepsy. So far, no treatment has been developed ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Production of radiometal-based radiopharmaceuticals at a clinical scale via droplet-scale radiochemistry

    SBC: DropletPharm Inc.            Topic: NIBIB

    PROJECT SUMMARY Despite the enormous value of radiopharmaceuticals for imaging and therapy in clinical nuclear medicine, and for research and drug development, the production of these compounds remains very expensive because of the need for complex, capital-intensive equipment and infrastructure (i.e., hot cells, stack monitor, radiosynthesizer, and a suite of QC testing equipment) at each site. F ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government